eFFECTOR Therapeutics, Inc.
EFTRDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Tomivosertib
Non-small Cell Lung Cancer
eFT508
Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Tomivosertib (eFT-508)
Solid Tumors
eFT226
Solid Tumor, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tomivosertib | Phase 2 | Non-small Cell Lung Cancer | - | - |
eFT508 | Phase 2 | Microsatellite Stable Relapsed or Refractory Colorectal Cancer | - | - |
Tomivosertib (eFT-508) | Phase 2 | Solid Tumors | - | - |
eFT226 | Phase 2 | Solid Tumor, Adult | - | - |
Frequently asked questions
What is in eFFECTOR Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in eFFECTOR Therapeutics, Inc.'s (EFTR) pipeline across Phase 2. Its lead program is Tomivosertib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is eFFECTOR Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for eFFECTOR Therapeutics, Inc. (EFTR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EFTR biotech catalysts?→
Add EFTR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow eFFECTOR Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.